Latest News

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.

FDA approval is based on phase 3 FirstLight and RadiantLight trials, the first therapy to directly restore orexin signaling in adults with NT1.

Oral encapsulated FMT increased peanut reactivity thresholds in 6 of 15 adults, tied to RORγt+ Treg cell expansion.

A JAMA study of nearly 25,000 vitiligo patients reveals major gaps in real-world treatment duration and consistency.

A study found children with and without food allergy screen positive for possible ARFID at similar rates, Daniela Ciciulla, APD, CEDC, says.

The FDA approved a 12-hour OTC combination of guaifenesin, dextromethorphan, and naproxen for cold and influenza symptom relief.

Tomashefski discusses where AATD diagnoses go missed and why APPs are positioned to close the gap.

Centanafadine FDA approval, DT120 EMERGE trial results, and COMP360 psilocybin data headline this month's psychiatry coverage.

Hepatology in July 2026: Odevixibat misses phase 3 primary endpoint, zabopegdutide shows early MASH benefit, plus a new Wilson disease NDA

This episode covers the recently announced topline data from the TRIUMPH-2 and TRIUMPH-3 phase 3 trials, as well as a study investigating online GLP-1 sales.

Highlights include an exploratory nerandomilast mortality analysis, the first North American bronchiectasis guideline from CHEST, and more.

The FDA has granted Fast Track designation to PVX108, Aravax's investigational peptide immunotherapy for peanut allergy, ahead of phase 2 data expected later in 2026.

Sibeprenlimab (Voyxact) achieves KDIGO goal, stabilizing eGFR decline in IgA nephropathy at 2-year Phase 3 VISIONARY readout.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia and the FDA approval of Furoscix ReadyFlow.

The conditional recommendations cover antibiotic therapy, long-term prevention strategies, airway clearance, and more.

Nephrology in July 2026: FDA approvals for atacicept, iptacopan, and Furoscix in IgAN/CKD, plus new IgAN and CKD trial data.

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

Angelika Erwin, MD, PhD, joins the podcast to discuss diagnosing and managing EPP and XLP on ABCs in Dermatology.

Catch up on July dermatology news: vitiligo and alopecia data, a pipeline discontinuation, psoriasis comparisons, and an FDA sNDA acceptance.

FDA expands Ryaltris to younger children with seasonal allergic rhinitis, Palforzia discontinues, and HAE's oral pipeline widens with deucrictibant and sebetralstat.

July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.